Abstract
Acne vulgaris is a common condition in adolescence and also for many women of childbearing age. The management of acne in pregnancy is complicated by the lack of clinical studies and pharmacokinetic data in this patient population and safety concerns regarding retinoid use in pregnancy. Of primary concern to both patients and clinicians is the safety profile of medications used during pregnancy. This review seeks to clarify what management options are available to treat acne during pregnancy and what data are available to guide decision making. Topical treatments are considered the safest option during pregnancy. They have the best safety profile and minimize the levels of systemic absorption, and therefore the least risk of fetal exposure. If these are applied properly with a strong emphasis on adherence, excellent results can be achieved.
Similar content being viewed by others
References:
Smithard A, Glazebrook C, Williams HC. Acne prevalence, knowledge about acne and psychological morbidity in mid-adolescence: a community-based study. Br J Dermatol. 2001;145:274–9.
Bhate K, Williams HC. Epidemiology of acne vulgaris. Br J Dermatol. 2013;168:474–85.
Williams C, Layton AM. Persistent acne in women: implications for the patient and for therapy. Am J Clin Dermatol. 2006;7(5):281–90.
Shafer T, Nienhaus A, Vieluf D, et al. Epidemiology of acne in the general population: the risk of smoking. Br J Dermatol. 2001;145:100–4.
Burton JL, Cunliffe WJ, Stafford I, et al. The prevalence of acne vulgaris in adolescence. Br J Dermatol. 1971;85:119–26.
US Food and Drug Administration. List of pregnancy exposure registries [online]. http://www.fda.gov/scienceresearch/specialtopics/womenshealthresearch/ucm134848.htm (Accessed 12 Dec 2012).
FDA Consumer Health Information. Pregnant women to benefit from better information [online]. http://www.fda.gov/downloads/ForConsumers/ConsumerUpdates/UCM143746.pdf (Accessed 12 Dec 2012).
Strauss JS, Krowchuk DP, Leyden JJ, et al. Guidelines of care for acne vulgaris management. J Am Acad Dermatol. 2007;56:651–63.
Nast A, Dréno B, Bettoli V, et al. European evidence-based (S3) guidelines for the treatment of acne. J Eur Acad Dermatol Venereol. 2012;26:1–29.
Elling SV, Powell FC. Physiological changes in the skin during pregnancy. Clin Dermatol. 1997;15:35–43.
Burton JL, Cunliffe WJ, Millar DG, Shuster S. Effect of pregnancy on sebum excretion. BMJ. 1970;2:769–71.
Muzaffar F, Hussain I, Haroon TS. Physiologic skin changes during pregnancy: a study of 140 cases. Int J Dermatol. 1998;37:429–31.
Dawes M, Chowienczyk PJ. Drugs in pregnancy: pharmacokinetics in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2001;15:819–26.
Loebstein R, Lalkin A, Koren G. Pharmacokinetic changes during pregnancy and their clinical relevance. Clin Pharmacokinet. 1997;33:328–43.
Boothby LA, Doering PL. FDA labeling system for drugs in pregnancy. Ann Pharmacother. 2001;35:1485–9.
Public Affairs Committee of the Teratology Society. Teratology Public Affairs Committee position paper: pregnancy labeling for prescription drugs: ten years later. Birth Defects Res Part A Clin Mol Teratol. 2007;79:627–30.
Addis A, Sharabi S, Bonati M. Risk classification systems for drug use during pregnancy: are they a reliable source of information? Drug Saf. 2000;23(3):245–53.
US Food and Drug administration. Pregnancy and lactation labeling [online]. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Labeling/ucm093307.htm (Accessed 12 Dec 2012).
MIMS USA drug information system [online]: http://www.mims.com/USA/Viewer/Html/PregDef.htm (Accessed 12 Dec 2012).
Tanghetti E. The evolution of benzoyl peroxide therapy. Cutis. 2008;82(5 Suppl.):5–11.
Yeung D, Nacht S, Bucks D, Maibach HI. Benzoyl peroxide: percutaneous penetration and metabolic disposition. II. Effect of concentration. J Am Acad Dermatol. 1983;9:920–4.
Nacht S, Yeung D, Beasley JN, et al. Benzoyl peroxide: percutaneous penetration and metabolic disposition. J Am Acad Dermatol. 1981;4(1):31–7.
Camera G, Pregliasco P. Ear malformation in baby born to mother using tretinoin cream. Lancet. 1992;339:687.
Lipson AH, Collins C, Webster W. Multiple congenital defects associated with maternal use of topical tretinoin. Lancet. 1993;341:1352–3.
Selcen D, Seidman S, Nigro MA. Otocerebral anomalies associated with topical tretinoin use. Brain Dev. 2000;22:218–20.
Navarre-Belhassen C, Blanchet P, Hillaire-Buys D, et al. Multiple congenital malformations associated with topical tretinoin. Ann Pharmacother. 1998;32:505–6.
Autret E, Berjot M, Jonville-Béra A-P, et al. Anophthalmia and agenesis of optic chiasma associated with adapalene gel in early pregnancy. Lancet. 1997;350:339.
Organisation of Teratology Information specialists. Tretinoin (Retin-A®) and pregnancy [online]. http://www.otispregnancy.org/files/tretinoin.pdf (Accessed 12 Dec 2012).
Jick SS, Terris BZ, Jick H. First trimester topical tretinoin and congenital disorders. Lancet. 1993;341:1181–2.
Panchaud P, Csajka C, Merlob P, et al. Pregnancy outcome following exposure to topical retinoids: a multicentre prospective study. J Clin Pharmacol. 2012;52:1844–51.
Van Hoogdalem EJ. Transdermal absorption of topical anti-acne agents in man; review of clinical pharmacokinetic data. J Eur Acad Dermatol Venereol. 1998;11 Suppl. 1:S13–9.
Akhavan A, Bershad S. Topical acne drugs: review of clinical properties, systemic exposure and safety. Am J Clin Dermatol. 2003;4:473–92.
Joint Formulary Committee. British National Formulary. 64th ed. London: BMJ Group and Pharmaceutical Press; 2012.
Frampton JE, Wagstaff AJ. Azelaic acid 15% gel in treatment of papulopustular rosacea. Am J Clin Dermatol. 2004;5:57–64.
Täuber U, Weiss C, Matthes H. Percutaneous absorption of azelaic acid in humans. Exp Dermatol. 1992;1:176–9.
Koren G, Pastuszak A, Ito S. Drugs in pregnancy. N Engl J Med. 1998;338:1128–37.
Feldmann RJ, Maibach HI. Absorption of organic compounds through the skin in man. J Invest Dermatol. 1970;54:399–404.
Dreno B, Bettoli V, Ochsendorf F, et al. European recommendations on the use of oral antibiotics for acne. Eur J Dermatol. 2004;14:391–9.
Harkaway KS, McGinley KJ, Foglia AN, et al. Antibiotic resistance patterns in coagulase-negative staphylococci after treatment with topical erythromycin, benzoyl peroxide, and combination therapy. Br J Dermatol. 1992;126:586–90.
Hernandez S, Werler MM, Walker AM, et al. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med. 2000;343:1608–14.
Hale EK, Pomeranz MK. Dermatological agents during pregnancy and lactation: an update and clinical review. Int J Dermatol. 2002;41:197–203.
Cunliffe WJ, C’otterill JA, Williamson B. The effect of clindamycin in acne: a clinical and laboratory investigation. Br J Dermatol. 1972;87:37–41.
Tan SG, Cunliffe WJ. The unwanted effects of clindamycin in acne. Br J Dermatol. 1976;94:313–5.
Owens RC, Donskey CJ, Gayens RP, et al. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis. 2008;46(Suppl. 1):S19–31.
Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2008.
Romøren M, Lindbæk M, Nordeng H. Pregnancy outcome after gestational exposure to erythromycin: a population-based register study from Norway. Br J Clin Pharmacol. 2012;74:1053–62.
Thiboutot D, Gollnick H, Bettoli V, et al. New insights into the management of acne: an update from the Global Alliance to improve outcomes in acne group. J Am Acad Dermatol. 2009;60(5 Suppl.):S1–50.
Sweetman SC, et al. Martindale: the complete drug reference. 34th ed. London: Pharmaceutical Press; 2005.
Kus S, Yucelten D, Aytug A. Comparison of efficacy of azithromycin vs. doxycycline in the treatment of acne vulgaris. Clin Exp Dermatol. 2004;30:215–20.
UK Medicines and Healthcare products Regulatory Agency (MHRA) azithromycin UKPAR (UK Public Assessment Reports for medicines). http://www.mhra.gov.uk/home/groups/pl-a/documents/websiteresources/con023376.pdf (Accessed 4 July 2013).
Goodfellow A, Alaghband-Zadeh J, Carter G, et al. Oral spironolactone improves acne vulgaris and reduces sebum excretion. Br J Dermatol. 1984;111:209–14.
Muhlemann MF, Carter GD, Cream JJ, Wise P. Oral spironolactone: an effective treatment for acne vulgaris in women. Br J Dermatol. 1986;115:227–32.
Jaussan V, Lemarchand-Beraud T, Gomez F. Modifications of the gonadal function in the adult rat after fetal exposure to spironolactone. Biol Reprod. 1985;32:1051–61.
Goodfield MJ, Cox NH, Bowser A, et al. Advice on the safe introduction and continued use of isotretinoin in acne in the U.K.: 2010. Br J Dermatol. 2010;162:1172–9.
Lammer EJ, Chen DT, Hoar RM, et al. Retinoic acid embryopathy. N Engl J Med. 1985;313:837–41.
Dreno B, Blouin E. Acne, pregnant women and zinc salts: a literature review. Ann Dermatol Venereol. 2008;135(1):27–33.
Du-Thanh A, Klugr N, Bensalleh H, Guillot B. Drug-induced acneiform eruption. Am J Clin Dermatol. 2011;12:233–45.
Seukeran DC, Cunliffe WJ. The treatment of acne fulminans: a review of 25 cases. Br J Dermatol. 1999;141:307–9.
Gur C, Diav-Citrin O, Shechtman S, et al. Pregnancy outcome after first trimester exposure to corticosteroids: a prospective controlled study. Reprod Toxicol. 2004;18:93–101.
Committee on safety of medicines/medicines control agency. Systemic corticosteroids in pregnancy and lactation. Curr Probl. 1998;24:9. http://www.mhra.gov.uk/home/groups/pl-p/documents/websiteresources/con2023392.pdf (Accessed 28 June 2013).
Ross EV. Optical treatments for acne. Dermatol Ther. 2005;18:253–66.
Car J, Car M, Hamilton F, et al. Light therapies for acne (intervention protocol). Cochrane Database Syst Rev. 2009;(3):CD007917.
Sakamoto FH, Torezan L, Anderson R. Photodynamic therapy for acne vulgaris: a critical review from basics to clinical practice: part II. Understanding parameters for acne treatment with photodynamic therapy. J Am Acad Dermatol. 2010;63:195–211.
Zeichner JA. Narrowband UV-B phototherapy for the treatment of acne vulgaris during pregnancy. Arch Dermatol. 2011;147:537–9.
Cunliffe WJ, Holland DB, Clark SM, Stables GI. Comedogenesis: some new aetiological, clinical and therapeutic strategies. Br J Dermatol. 2000;142:1084–91.
Zip C. A practical guide to dermatological drug use in pregnancy. Skin Ther Lett. 2006;11:1–4.
Crider KS, Cleves MA, Reefhuis J, et al. Antibacterial medication use during pregnancy and risk of birth defects. Arch Pediatr Adolesc Med. 2009;163(11):978–85.
Acknowledgments
Both authors have no relevant conflicts of interest. FMM researched and drafted the initial document, which was then reviewed and edited by ADO.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Meredith, F.M., Ormerod, A.D. The Management of Acne Vulgaris in Pregnancy. Am J Clin Dermatol 14, 351–358 (2013). https://doi.org/10.1007/s40257-013-0041-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40257-013-0041-9